Literature DB >> 21181216

A molecular dynamics study on opioid activities of biphalin molecule.

Jin-Yuan Hsieh1, Tzen-Yuh Chiang, Jun-Liang Chen, Yun-Wen Chen, Hong-Chang Lin, Chi-Chuan Hwang.   

Abstract

Molecular dynamics simulations of the biphalin molecule, (Tyr-D-Ala-Gly-Phe-NH)(2), and the active tetrapeptide hydrazide, Tyr-D-Ala-Gly-Phe-NH-NH(2) were performed to investigate the cause of the increased μ and δ receptor binding affinities of the former over the latter. The simulation results demonstrate that the acylation of the two equal tetrapeptide fragments of biphalin produces the constrained hydrazide bridges [Formula: see text] and [Formula: see text], which in turn increase the opportunity of conformations for binding to μ or δ receptors. Meanwhile, the connection of the two active tetrapeptide fragments of biphalin also results in the constrained side chain torsion angle χ(2) at one of the two residues Phe. This constrained side chain torsion angle not only significantly increases the δ receptor binding affinity but also makes most of the δ receptor binding conformations of biphalin bind to the δ receptor through the fragment containing the mentioned residue Phe.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181216     DOI: 10.1007/s00894-010-0931-1

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  17 in total

Review 1.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 2.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

3.  Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration.

Authors:  B S Silbert; A W Lipkowski; M S Cepeda; S K Szyfelbein; P F Osgood; D B Carr
Journal:  Agents Actions       Date:  1991-07

Review 4.  delta-Opioid receptor subtypes and cross-talk with mu-receptors.

Authors:  J R Traynor; J Elliott
Journal:  Trends Pharmacol Sci       Date:  1993-03       Impact factor: 14.819

5.  Antinociceptive profile of biphalin, a dimeric enkephalin analog.

Authors:  P J Horan; A Mattia; E J Bilsky; S Weber; T P Davis; H I Yamamura; E Malatynska; S M Appleyard; J Slaninova; A Misicka
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

6.  Both mu and delta opiate receptors exist on the same neuron.

Authors:  T M Egan; R A North
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

7.  Dimeric tetrapeptide enkephalins display extraordinary selectivity for the delta opiate receptor.

Authors:  Y Shimohigashi; T Costa; H C Chen; D Rodbard
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

8.  Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives.

Authors:  T J Abbruscato; S A Williams; A Misicka; A W Lipkowski; V J Hruby; T P Davis
Journal:  J Pharmacol Exp Ther       Date:  1996-03       Impact factor: 4.030

9.  Delta opioid receptor selective ligands; DPLPE-deltorphin chimeric peptide analogues.

Authors:  A Misicka; A W Lipkowski; R Horvath; P Davis; F Porreca; H I Yamamura; V J Hruby
Journal:  Int J Pept Protein Res       Date:  1994-07

10.  A topochemical approach to explain morphiceptin bioactivity.

Authors:  T Yamazaki; S Ro; M Goodman; N N Chung; P W Schiller
Journal:  J Med Chem       Date:  1993-03-19       Impact factor: 7.446

View more
  1 in total

1.  Cyclic Biphalin Analogues Incorporating a Xylene Bridge: Synthesis, Characterization, and Biological Profile.

Authors:  Azzurra Stefanucci; Alfonso Carotenuto; Giorgia Macedonio; Ettore Novellino; Stefano Pieretti; Francesca Marzoli; Edina Szűcs; Anna I Erdei; Ferenc Zádor; Sándor Benyhe; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2017-07-12       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.